EP1123705A1 — Pharmaceutical combinations for treating lower urinary tract disfunctions
Assigned to Novartis International Pharmaceutical Ltd · Expires 2001-08-16 · 25y expired
What this patent protects
This invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia in men, which combinations contain- an alpha-adrenoceptor antagonist and a muscarinic antagonist. The combinations of the inve…
USPTO Abstract
This invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia in men, which combinations contain- an alpha-adrenoceptor antagonist and a muscarinic antagonist. The combinations of the invention are particularly suitable for treating moderate or severe lower urinary tract symptoms.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.